Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2010

View Archived Issues

NicOx's NO-donating agents show preclinical promise in ophthalmology and pain

Serum bilirubin modulates response to bucindolol in patients with heart failure

Potent inhibitors identified of GIST-relevant kinases

Merck & Co. claims new cholesterol absorption inhibitors

Merck & Co. presents new sst5 receptor antagonists

NeuroSearch discovers new monoamine reuptake inhibitors

GlaxoSmithKline presents new AMPA receptor agonists

TransTech and Forest enter into agreement to develop GKAs

Vivalis and Sanofi Pasteur join to discover MAbs for infectious diseases

Nautilus Neurosciences launches Cambia for migraine in the U.S.

Simvastatin/ezetimibe combination promotes tumor growth in prostate cancer model

QBI-139 enters phase I trial in advanced/refractory solid tumors

Inhaled formoterol fumarate/glycopyrrolate is safe in healthy subjects

Protalix BioTherapeutics completes phase I trial of PRX-105

European Commission extends indication of RoActemra

Phase II data reported on IFN alpha-2b in patients with anogenital warts

Discovery receives FDA guidance for preclinical Surfaxin program in neonatal RDS

Idera reports preliminary phase I data on IMO-3100

Nektar Therapeutics reports phase II data on NKTR-102 in breast cancer

Aerovance presents phase IIb data on pitrakinra in eosinophilic asthma

NanoViricides' anti-HIV candidates efficacious against two HIV-1 isolates in vitro

Columbia Labs completes enrollment in phase III Prochieve trial

Eisai and Helsinn enter license agreement for antiemetic combination agent

Engrailed-2 proposed as diagnostic biomarker for prostate cancer

Phase III lubiprostone trial in idiopathic constipation complete

Eisai presents the year's product and financial highlights

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...